Copyright
©The Author(s) 2015.
World J Hepatol. Mar 27, 2015; 7(3): 521-531
Published online Mar 27, 2015. doi: 10.4254/wjh.v7.i3.521
Published online Mar 27, 2015. doi: 10.4254/wjh.v7.i3.521
Table 3 Overall survival in the first cohort of patients using the ART score calculated before the second transarterial chemoembolisation with a cut-off value of: 0-1.5 vs≥ 2.5
| ART(n = 139) | ART[0](n = 67) | ART[1](n = 11) | ART[1.5](n = 18) | ART[2.5](n = 3) | ART[3](n = 2) | ART[4](n = 16) | ART[5](n = 5) | ART[5.5](n = 5) | ART[6.5](n = 3) | ART[7](n = 2) | ART[8](n = 7) |
| Median-survival, mo (95%CI) | 37 (31-42) | 9 (7-14) | 28 (25-40) | 10 (5-27) | 17 (12-21) | 28 (7-36) | 14 (12-16) | 13 (6-15) | 5 (3-5) | 22 (8-36) | 5 (4-11) |
| 34 (28-38) | 13 (10-16) | ||||||||||
| P value ART (0, 1.5) vs ART ≥ 2.5 | < 0.0001 | ||||||||||
- Citation: Adhoute X, Penaranda G, Castellani P, Perrier H, Bourliere M. Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system? World J Hepatol 2015; 7(3): 521-531
- URL: https://www.wjgnet.com/1948-5182/full/v7/i3/521.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i3.521